Skip to content
karyopharm-logo Logo for Karyopharm
Main Menu
  • Contact
  • Clinical Trials
  • Careers
  • Follow Us
  • LinkedIn
  • Twitter
  • About
    • About Karyopharm
    • Management Team
    • Board of Directors
    • Careers at Karyopharm
  • Science
    • XPO1 Inhibition
    • Pipeline
  • Our Medicines
  • Patients
    • Overview
    • Multiple Myeloma
    • Diffuse Large B-Cell Lymphoma (DLBCL)
    • Clinical Trials
    • Patient Resources
  • Responsibility
    • Supporting Medical Research
    • Expanded Access
    • Grants & Giving
    • Corporate Sustainability
  • Investors
    • Corporate Profile
    • Press Releases
    • Events & Presentations
    • Corporate Governance
      • Management Team
      • Board of Directors
      • Committee Composition
      • Contact the Board
    • Financial Information
      • SEC Filings
      • Annual Reports & Proxy Statements
      • Quarterly Results
      • Key Ratios
    • Stock Information
      • Interactive Chart
      • Investment Calculator
      • Historical Stock Price
    • Analyst Coverage
    • Investor FAQs
    • Publications and Presentations
    • Corporate Sustainability
    • Contact Us
      • Contact Us
      • Investor Alerts

Resources

Presentation

KPT-0127 Induces Selective Apoptosis of Malignant Cells by CRM1 Inhibition and Elevation of Regulatory Proteins p53, p21, FOXO and IkB

  • PDF (1.24 MB)
Read More
Presentation

KPT-0127, a Novel, Potent and Selective Inhibitor of CRM1-Mediated Nuclear Export Shows Selective Cytotoxicity for the Treatment of Hematological Cancers

  • PDF (1.17 MB)
Read More
Previous 1 … 20 21 22
© Karyopharm, 2024. All Rights Reserved.
  • Terms of Use
  • Privacy Policy
  • Site Map